Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sarepta Therapeutics (SRPT)
NASDAQ:SRPT
Holding SRPT?
Track your performance easily
SRPT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$102.16 - $173.25
Previous CloseN/A
Volume185.86K
Average Volume (3M)704.03K
Market Cap
$11.18B
Enterprise Value$12.74B
Total Cash (Recent Filing)$317.85M
Total Debt (Recent Filing)$6.04M
Price to Earnings (P/E)98.0
Beta0.75
Next Earnings
Mar 04, 2025EPS Estimate
1.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.20
Shares Outstanding95,519,650
10 Day Avg. Volume806,945
30 Day Avg. Volume704,033
Standard Deviation0.14
R-Squared0.08
Alpha0.00154
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.82
Price to Cash Flow (P/CF)-39.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.14
Enterprise Value/Revenue7.77
Enterprise Value/Gross Profit11.66
Enterprise Value/Ebitda67.85
Forecast
1Y Price Target
$180.87Price Target Upside53.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
Sarepta Therapeutics News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceSarepta reported another quarter of outperformance for 4Q24, with preliminary total products revenues approximately 11% above consensus, driven by significant upside from Elevidys and exon-skipping sales.
Growth PotentialWith only about 5% of the current eligible patient population treated with Elevidys, there is significant room to drive growth.
Product DemandSarepta Therapeutics Inc. is enthusiastic about the Elevidys launch and sees a massive amount of demand for the product.
Bears Say
EarningsInvestors are likely disappointed that management didn't raise their 2025 product sales guidance.
Financial PerformanceSarepta's other three products have shown relatively low sequential growth over the past two years, focusing concerns on Elevidys's growth prospects.
Market RisksThere is considerable risk in payers not adding older and/or non-ambulatory DMD patients to their drug formulary for Elevidys.
---
Ownership Overview
4.09% Insiders
29.52% Mutual Funds
0.16% Other Institutional Investors
45.82% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SRPT FAQ
What was Sarepta Therapeutics’s price range in the past 12 months?
Sarepta Therapeutics lowest stock price was $102.16 and its highest was $173.25 in the past 12 months.
What is Sarepta Therapeutics’s market cap?
Sarepta Therapeutics’s market cap is $11.18B.
When is Sarepta Therapeutics’s upcoming earnings report date?
Sarepta Therapeutics’s upcoming earnings report date is Mar 04, 2025 which is in 42 days.
How were Sarepta Therapeutics’s earnings last quarter?
Sarepta Therapeutics released its earnings results on Nov 06, 2024. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of -$0.075 by $0.415.
Is Sarepta Therapeutics overvalued?
According to Wall Street analysts Sarepta Therapeutics’s price is currently Undervalued.
Does Sarepta Therapeutics pay dividends?
Sarepta Therapeutics does not currently pay dividends.
What is Sarepta Therapeutics’s EPS estimate?
Sarepta Therapeutics’s EPS estimate is 1.77.
How many shares outstanding does Sarepta Therapeutics have?
Sarepta Therapeutics has 95,519,650 shares outstanding.
What happened to Sarepta Therapeutics’s price movement after its last earnings report?
Sarepta Therapeutics reported an EPS of $0.34 in its last earnings report, beating expectations of -$0.075. Following the earnings report the stock price went down -5.9%.
Which hedge fund is a major shareholder of Sarepta Therapeutics?
Among the largest hedge funds holding Sarepta Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds Sarepta Therapeutics’s shares valued at 322M.
---
Sarepta Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$180.87 (53.28% Upside)
$180.87 (53.28% Upside)
Blogger Sentiment
Bullish
SRPT Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 471.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 4.5%
Last 30 Days ▲ 4.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.81%
12-Months-Change
Fundamentals
Return on Equity
9.98%
Trailing 12-Months
Asset Growth
15.76%
Trailing 12-Months
Company Description
Sarepta Therapeutics
Sarepta Therapeutics, Inc. is a leading biotechnology company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, the company is particularly recognized for its work in developing therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. Sarepta's core products are based on its proprietary RNA-targeted exon-skipping technology, which aims to address the underlying genetic causes of DMD.
---
SRPT Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and sustained profitability, driven by the impressive performance of ELEVIDYS and the PMO franchise. Despite the setback of discontinuing the SRP-5051 program, Sarepta's financial health remains robust, and confidence in future performance is high.Read More>---
SRPT Stock 12 Month Forecast
Average Price Target
$180.87
▲(53.28% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Exelixis
―
Vertex Pharmaceuticals
―
PTC Therapeutics
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering SRPT
1 Year
---